非药物干预与脂肪肝愈后复发相关性的随访调查

Relativity study of non-drug intervention and relapse after cure of fatty liver

目的了解脂肪肝愈后复发与非药物干预的相关性以及治疗脂肪肝所用药物干预品种的相关性。方法选择脂肪肝治愈者两组与健康观察者1组共计2088例，其中柴苓降脂方治疗组1140例，血脂康加护肝片联合治疗组924例，健康观察组24例。均采用以痊愈后停药的第3、6个月和1年末连续召回原就诊医院复诊各1次并同时随访记录，和1年后以建立随访调查记录卡方式，在每年的2~-3月份电话随访1次，连续跟踪随访7年。进行分组分类统计比较。结果3组中坚持继续进行积极非药物干预者，脂肪肝的复发（发病）率和相关疾病的发病率明显降低，与不坚持非药物干预者比较，均具有明显的统计学意义（P〈O．01），而组间比较差异无统计学意义（P〉0．05）。结论脂肪肝愈后复发率及相关疾病的发病率与停药后是否能继续坚持非药物干预具有明显的相关性，而与治疗脂肪肝所用干预药物品种无明显相关性。提倡脂肪肝合并高脂血症患者愈后要坚持进行非药物性干预，以降低复发率和减少相关疾病的发病率。

[ Objective ] To understand the relativity of the relapse after cure of fatty liver （hepatic adipose infil- tration） and nun-drug intervention, and the relativity of the used drug intervention. [ Methods ] A total of 2088 eases including two groups of healers and one group of health observations were chosen, 1140 cases of which were treated with Chailingjiangzhi decoction, 924 cases were treated with Xuezhikang tablets, and 24 cases were heath. All the recovered patients got a further consultation and follow-up records at the end of the third month, the sixth month and the first year. The investigating cards were set up one year later. Every February to March, the patients would be called and interviewed which would be lasted for 7 years. [ Results ] In the three groups, the fatty liver recurrence and relative coincidence were reduced obviously for all the recovered patients who insisted on being treated by non- drug intervention, and there was clear statistic significance （P 〈 0.01）. There was no significant difference in the comparison between two groups （P 〉 0.05）. [ Conclusions] There is obvious relativity for the liver recurrence whether or not to insist on using non-drug intervention. There is no obvious relativity among what kind of drug inter- vention the patients used. The patients suffered from fatty liver along with hyperlipdemia, had better to insist on us- ing non-drug intervention after they have recovered, so as to reduce the recurrence and complications.